ClinicalTrials.gg
CompletedNCT01865305Updated Oct 23, 2015

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

A Phase 1 interventional study of insulin degludec/insulin aspart 30 and insulin degludec/insulin aspart 40 in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-23.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.

Enrollment
297th of 494
59 · median 87
Started
2006
with 52 others
Phase 1
206 of 642
1 open now
Registered
480th of 642
by date

Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 297th largest by enrollment of the 494 interventional ones that give a count, is one of 53 that started in 2006, is one of 206 in phase 1, and was the 480th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 69 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 642 studies in Diabetes Mellitus by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to compare different ratios of explorative formulations, not similar to the proposed commercial formulation, of IDegAsp (co-formulation of insulin degludec/insulin aspart and insulin aspart) with separately injected, simultaneous doses of insulin degludec (insulin 454), and insulin aspart, compared with biphasic insulin aspart 30 in male subjects with type 1 and type 2 diabetes mellitus.

Trial part 1 is a five-period cross-over trial with incomplete block-design in subjects with type 1 diabetes where each subject will be randomised to five out of the ten possible treatments. Each treatment consists of an injection of the insulin product followed by a euglycemic clamp with a washout period of 7-15 days between treatments.

Trial part 2 is a three-period cross-over trial with complete blockdesign in subjects with type 2 diabetes. Each treatment consists of an injection of the insulin product followed by a euglycaemic clamp with a washout period of 7-15 days between treatments.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject will be a male volunteer, who is considered to be generally healthy, except for underlying diabetes mellitus and concomitant medical complications (e.g. hypertension) based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator
  • Glycosylated (HbA1c) below or equal to 10 % based on central laboratory results
  • ADDITIONAL INCLUSION CRITERA FOR SUBJECTS WITH TYPE 1 DIABETES:
  • Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12 months
  • (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive)
  • ADDITIONAL INCLUSION CRITERA FOR SUBJECTS WITH TYPE 2 DIABETES:
  • Diagnosed with type 2 diabetes mellitus for at least 12 months
  • Treated with insulin for the last 3 months prior to screening.
  • Body Mass Index (BMI) between 22.0 and 35.0 kg/m\^2 (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • A subject with a history of significant multiple drug allergies or with a known or suspected allergy to the trial product or any medicine chemically related to the trial product, as judged by the Investigator
  • A subject who has participated in any other trials involving products within the 3 months preceding the start of dosing
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Trial part 1

    Drug: insulin degludec/insulin aspart 30 · Drug: insulin degludec/insulin aspart 40 · Drug: insulin degludec/insulin aspart 50 · Drug: insulin degludec · Drug: insulin aspart · Drug: biphasic insulin aspart 30

  • Experimental
    Trial part 2

    Drug: insulin degludec/insulin aspart 40 · Drug: insulin degludec/insulin aspart 50 · Drug: biphasic insulin aspart 30

Interventions

  • Druginsulin degludec/insulin aspart 30

    Single dose administrated subcutaneously (s.c., under the skin).

  • Druginsulin degludec/insulin aspart 40

    Single dose administrated subcutaneously (s.c., under the skin).

  • Druginsulin degludec/insulin aspart 50

    Single dose administrated subcutaneously (s.c., under the skin).

  • Single dose administrated subcutaneously (s.c., under the skin).

  • Single dose administrated subcutaneously (s.c., under the skin).

  • Drugbiphasic insulin aspart 30

    Single dose administrated subcutaneously (s.c., under the skin) as comparator.

  • Druginsulin degludec/insulin aspart 40

    Single dose administrated subcutaneously (s.c., under the skin).

  • Druginsulin degludec/insulin aspart 50

    Single dose administrated subcutaneously (s.c., under the skin).

  • Drugbiphasic insulin aspart 30

    Single dose administrated subcutaneously (s.c., under the skin).

06

What researchers measure

Primary outcomes

  1. Area under the insulin aspart concentration curve from 0-2 hours (for subjects with type 1 diabetes)

    Time frame: 0-2 hours after dosing

  2. Maximum glucose infusion rate divided by the average glucose infusion rate (for subjects with type 2 diabetes)

    Time frame: 0-24 hours after dosing

Secondary outcomes

  1. Area under the glucose infusion rate curve

    Time frame: 0-24 hours after dosing

  2. Area under the serum insulin degludec concentration curve

    Time frame: 0-96 hours after dosing

07

Study locations

1 site
  • Neuss, 41460, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2013
First posted
May 30, 2013
Start
Sep 2006
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Last update
Oct 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01865305
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 30, 2013
Start date
Sep 2006
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Oct 23, 2015

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion